Glenmark receives final ANDA approval for Omeprazole DR Capsules

05 Nov 2014 Evaluate

Glenmark Generics Inc., USA (GGI) the subsidiary of Glenmark Generics has been granted final approval for its abbreviated new drug application (ANDA) from the United States Food and Drug Administration (USFDA) for Omeprazole Delayed Release Capsules, their generic version of Prilosec by AstraZeneca.

Omeprazole DR Capsules are indicated for the short-term treatment of active duodenal ulcer in adults. The approval is for the 10, 20, and 40mg strengths of Omeprazole. According to IMS Health sales data for the 12 month period ending September 2014, Omeprazole garnered annual sales of approximately $520 million.

Glenmark’s current portfolio consists of 94 products authorized for distribution in the US marketplace and 72 ANDA’s pending approval with the USFDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

Glenmark Pharma Share Price

1956.40 3.50 (0.18%)
11-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1806.90
Dr. Reddys Lab 1272.95
Cipla 1512.10
Zydus Lifesciences 922.45
Lupin 2080.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×